

Press release

Adenium Biotech completes the team hiring MD Edward Fang as CMO and PharmD Dorrit Andersen as regulatory responsible

Copenhagen, September 11 th, 2014.

Adenium Biotech has hired Dr Edward Fang as Chief Medical Officer.

Dr Fang comes from a position as Director, Clinical Sciences with Trius Therapeutics of San Diego, US.

Adenium Biotech has also hired Dr Dorrit Andersen as responsible for regulatory affairs. Dr Andersen is a private regulatory consultant and has previously worked as global regulatory project director with Novo Nordisk and regulatory affairs manager at Symphogen and Genmab.

Adenium Biotech is a spin out from Novozymes. The company is focusing on the development of anti microbial peptides against multi- and pan drug-resistant Gram-negative and -positive bacteria. There is a desperate need for new anti infectives to combat the ever increasing challenge of multi- or pan drug resistant pathogens. Adenium's antimicrobial peptides are novel, possess a unique MoA, have a very low spontaneous frequency of mutation and are rapidly cidal.

AA139 with potent activity against the four major Gram-negative GAIN pathogens *E. coli*, *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* is Adenium's most advanced program and is expected to initiate First-in-man (FIM) studies in Q4 2015.

Dr Peter Nordkild, CEO of Adenium: "With the addition of Edward and Dorrit we have completed the Adenium team. We are in the process of finalizing the IND enabling studies for AA139 and to present AA139 for the regulatory authorities. Preclinical tox/safety studies will be initiated in February next year. If everything goes according to plan we should be able to initiate FIM clinical studies before the end of 2015".

For further information please contact:

Peter Nordkild, MD

CEO, Adenium Biotech

TLF: 00 45 25 47 16 46

E-mail: pno@adeniumbiotech.com

About Adenium Biotech ApS.

Adenium Biotech is a Danish biopharmaceutical company spun out from Novozymes A/S in 2011. Adenium focuses on the development and commercialization of anti microbial peptides for the treatment of Gram-negative and -positive bacterial infections. Our focus is treatment of hospital acquired infections in particular complicated urinary tract infection and pneumonia caused by multi drug resistant Gram-negative bacteria as well as MRSA infections in patients with an osteo- or cardio implants. Adenium Biotech is managed by a small team of experts and supported by a very strong scientific advisory board.

